Product Name: p38g (1-15)
Product Number: PE-01AYJ95
Size: | 200 µg | | Price: | 45.00 |
| 1 mg | | $US | 90.00 |
| 5 mg | | | 211.00 |
Peptide Name: p38g (1-15)
Product Use: Services as a blocking peptide for use with the p38g-1 rabbit polyclonal antibody (Cat. No.: AB-NK059-3) that is also available from Kinexus. The peptide sequence is located in the N-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: MSSPPPARSGFYRQEC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1812.1 Da
Peptide Purity Percent after Synthesis and Purification: >90
Scientific Background: p38g (MAPK12, ERK6) is a protein-serine/threonine kinase of the CMGC group and p38 MAPK family. This kinase is moderate to highly expressed in most tested human tissues except in the pituitary, spinal cord and vagina, where it is notably absent. p38g is activated by phosphorylation at Y185 and probably T183. p38g is activated in response to stress. It has been linked with the development of inflammation, autoimmunity, diabetes and cancer. It functions as a signal transducer during myoblasts to myotubes differentiation. Enforced localization of p38g in the nucleus or cytoplasm markedly attenuates the ability of the kinase to induce cell cycle arrest in fibroblasts. p38g increases basal glucose uptake and decreases DNP- and contraction-stimulated glucose uptake, partially by affecting levels of glucose transporter expression in skeletal muscle. p38g overexpression is linked with highly metastatic breast cancer cell lines, and its expression is associated with the metastatic states of breast tumour samples. The gene was found to be deregulated in uterine leiomyoma. Loss of function may be important to confer survival and inhibit apoptosis for tumour cells.